


A



B


		% of GFP positive cells			
		Med	IL-4	CD40	IL-4+CD40
XF-1		0.5±0.2	1.0±0.3	1.9±0.2	2.7 ± 0.3 (3)
XF-5a		0.7±0.2	2.8±0.4	3.2±0.3	54.3 ± 5.4 (4)
XF-8		0.3±0.1	0.3±0.2	1.5±0.2	7.6 ± 2.3 (8)
XF-2b		0.8±0.3	0.9±0.2	2.8±0.3	3.1 ± 0.6 (4)
XF-2a		0.7±0.2	1.2±0.3	3.2±0.2	3.6 ± 0.7 (3)
XF-6a		0.9±0.3	2.9±0.3	3.8±0.5	28.6 ± 4.2 (4)
XF-6b		0.6±0.2	0.8±0.2	1.2±0.2	3.7 ± 0.7 (3)
XA-1					

FIGURE 1

The figure displays flow cytometry plots for GFP expression in XF-1 and XF-5a.1 cells. The top row shows the initial selection of GFP+ cells from a GFP- population. The bottom two rows show the effect of IL-4 and CD40 mAb on GFP expression in XF-1 and XF-5a.1 cells, respectively, under four conditions: Medium, IL-4, CD40 mAb, and IL-4+CD40. The plots are arranged in a grid, with the y-axis representing SSC and the x-axis representing GFP. Percentages indicate the proportion of GFP+ cells in each condition.

Cell Line	Condition	GFP+ (%)
XF-1	Medium	99.82%
	IL-4	98.97%
	CD40 mAb	98.01%
	IL-4+CD40	97.43%
XF-5a.1	Medium	99.35%
	IL-4	97.06%
	CD40 mAb	96.75%
	IL-4+CD40	41.15%

A



B



C




FIGURE 3

A

Sμ	TGGGCTGAGCTGGGCTGGGCTGGGCTGGGCTGAGCGGGTC 577	Sμ	TTGAACTGGGTTGAGCTGAGCTGAGCTGAGCTGGGCTAAG 452
15-15		16-16	
Sγ2	TGGGCTGAGCTGGGCTGGTGGAAAGCCAGGACGAGCAGGGG	Sγ2	TTGAACTGGGTTGAGCTGAGCAGAGCAGAGGCCACTGAGG
Sγ2	CAGCCACAGGTGAGCAGGCCGTGAGCAG-ACGAGCAGGGA 2292	Sγ2	CGTTCACGGAGCTGACCCAGCAGAGCAGAGGCCACTGAGG 1263
Sμ	CTAACAGGCTGAACTGGGCTGAGCTGAGCTGAACTGGGCT 409	Sμ	TGGGCTGGGCTGAGC-GGTCTAGCGGGCTGAGCTGAGCTG 597
41-44		41-27	
Sγ2	CTAACAGGCTGAACTGGGCTGGCAGGAGCTGGGTAGTTGC	Sγ2	TGGGCTGGGCTGAGCGGGTCAGCCTCCTGGTGCCGGGAAG
Sγ2	TCACTCAGCTCCTAGATTTTGGCAGGAGCTGGGTAGTTGC 2454	Sγ2	GGCTGGTGAAAGTGCACTGCAGCCTCCTGGTGCCAGGAAG 2512

B

Sγ2	AGGGAGCTGACCCAGCAGAGCAGAGGCCACTGAGGAGCTG 1310	Sγ2	CAGGAGGGTGGAAGCCCAAGAGCCAGAGCCAGAGGCAGG 1061
38-41		38-45	
Sμ	AGGGAGCTGACCCAGCAGAGCTGAGCGGGGCCGAGCGGGG	Sμ	CAGGAGGGTGGAAGCCCAAGGTGAAGTAGGGTGAGCTGGGC
Sμ	CTAGGCTGGGCTGGGCTGGGCTGAGCGGGGCTGAGC-GGG 817	Sμ	TGGGCTGGGCTGAGCTAAGCTGAAGTAGGGTGAGCTGGGC 1455
Sγ2	CAGGGGAGGCACAGGGGCTAGGCTCAGAGCCACCTGATGG 1103	Sγ2	TCCAGGGAGGCCCCAGAAAGGCCCCAGAGTGCAAGCAGGCCTG 1237
39-42		38-48	
Sμ	CAGGGGAGGCACAGGGCTAGGACCTGGACTGGGCTGAGC	Sμ	TCCAGGGAGGCCCCAGAAAGGAACCTGGGCTGGGCTGAGCT
Sμ	TGGTTTGGGCTGAGTTGAGCTGACCTGGACTGGGCTGAGC 1506	Sμ	AGCCGAGGCTGGGCTGGGCTAACCCTGGGCTGGGCTGAGCT 1396

C

Sμ	GCTGGGCTGGGCTGAGCTGGGCTGAGCTGGGCTGAGCAAG 638	Sμ	TGAGCTGAGCTGGGCTGGGCTGAGCTGGGCTGGGCTGGGC 562
40-43		40-45	
CD2	GCTGGGCTGAGCTGAGCTGGGCCCCCACCAAATTCAGCT	CD2	TGAGCTGAGCTGGGCTGGGCTTCGTCCCCCGCCTCCTGGA
CD2	TCATGAAGAAAGGGCCGGAAGCCCCACCAAATTCAGCT 821	CD2	TCGTCCCAGGCACCTAGTCATCGTCCCCCGCCTCCTGGA 914

FIGURE 4




FIGURE 5




FIGURE 6

FOUO-000000000000




FIGURE 7




FIGURE 7
(CONTINUED)

00770169.042604




FIGURE 8

09770169.012601




FIGURE 9

00720469.042604




FIGURE 10

00770169-042201


[illegible]

FIGURE 11

0970459.05601
T09210-6970460




FIGURE 12

09770169-012601




FIGURE 13

FIGURE 14